Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer-Reference-Cited by-同舟云学术

Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer

Published:2017-07-18 Issue:7 Volume:12 Page:e0181211
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Messaritakis Ippokratis,Politaki Eleni,Kotsakis Athanasios,Dermitzaki Eleftheria-Kleio,Koinis Filippos,Lagoudaki Eleni,Koutsopoulos Anastasios,Kallergi Galatea,Souglakos John,Georgoulias Vassilis^ORCID

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference45 articles.

1. (2009) American Cancer Society. Cancer Facts and Figures. Retrieved from http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2009/index.

2. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database;R Govindan;J Clin Oncol,2006

3. Small-cell lung cancer;DM Jackman;Lancet,2005

4. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104;M Takada;J Clin Oncol,2002

5. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide;AT Turrisi 3rd;N Engl J Med,1999

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in predictive biomarkers associated with immunotherapy in extensive-stage small cell lung cancer;Cell & Bioscience;2024-09-12

2. Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients;Molecular Oncology;2024-07-02

3. STIM1, ORAI1, and KDM2B in circulating tumor cells (CTCs) isolated from prostate cancer patients;Frontiers in Cell and Developmental Biology;2024-06-05

4. ES-SCLC Patients with PD-L1+ CTCs and High Percentages of CD8+PD-1+T Cells in Circulation Benefit from Front-Line Immunotherapy Treatment;Biomedicines;2024-01-10

5. Recent Progress in Enhanced Cancer Diagnosis, Prognosis, and Monitoring Using a Combined Analysis of the Number of Circulating Tumor Cells (CTCs) and Other Clinical Parameters;Cancers;2023-11-11